Compare · NN vs TMO
NN vs TMO
Side-by-side comparison of NextNav Inc. (NN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NN and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $232.67B, about 78.5x NN ($2.96B).
- Over the past year, NN is up 6.9% and TMO is up 28.2% - TMO leads by 21.4 points.
- TMO has been more active in the news (8 items in the past 4 weeks vs 7 for NN).
- TMO has more recent analyst coverage (25 ratings vs 7 for NN).
- Company
- NextNav Inc.
- Thermo Fisher Scientific Inc
- Price
- $17.55+1.33%
- $629.32+0.27%
- Market cap
- $2.96B
- $232.67B
- 1M return
- +38.59%
- +9.93%
- 1Y return
- +6.85%
- +28.22%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 8
- Recent ratings
- 7
- 25
NextNav Inc.
Spartacus Acquisition Corporation intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Duluth, Georgia.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest NN
- Amendment: SEC Form SCHEDULE 13G/A filed by NextNav Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by NextNav Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by NextNav Inc.
- SEC Form 10-Q filed by NextNav Inc.
- NextNav Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- NextNav Inc. Reports Second Quarter 2026 Results and Operational Highlights
- NextNav to Participate in August 2026 Conferences
- NextNav and Safran Electronics & Defense Announce Agreement to Demonstrate 5G-Powered PNT Interoperability
- NextNav Announces Date for Second Quarter 2026 Earnings Call
- Odeon initiated coverage on NextNav with a new price target
Latest TMO
- Sr. VP and Chief HR Officer Britt Lisa P. sold $7,014,093 worth of shares (11,440 units at $613.12) and exercised 11,440 shares at a strike of $418.32, decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Executive Vice President Shafer Michael D exercised 25,500 shares at a strike of $370.58 and sold $15,300,000 worth of shares (25,500 units at $600.00) as part of a pre-agreed trading plan (SEC Form 4)
- Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
- VP & Chief Accounting Officer Holmes Joseph R. exercised 420 shares at a strike of $309.63 and sold $245,620 worth of shares (420 units at $584.81) (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $2,862,002 worth of shares (4,883 units at $586.12) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. exercised 5,850 shares at a strike of $309.63 and sold $3,393,000 worth of shares (5,850 units at $580.00), decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,616,967 worth of shares (15,000 units at $574.46) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,628,434 worth of shares (15,000 units at $575.23) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- President & COO Pettiti Gianluca sold $226,000 worth of shares (400 units at $565.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,651 units (SEC Form 4)